Trial Profile

A Phase 1, Sequential Drug Interaction Study to Evaluate the Effect of CYP3A4 and P-glycoprotein Inhibition by Itraconazole or Induction by Rifampicin on the Pharmacokinetics of Ecopipam and Its Metabolites in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ecopipam (Primary) ; Itraconazole; Rifampicin
Indications Cardiovascular disorders; Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome; Restless legs syndrome; Speech disorders
Focus Pharmacokinetics
Sponsors Emalex Biosciences

28 Aug 2024 Status changed from recruiting to completed.
18 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 May 2024.
18 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com